Submit a Story!
topics:

- Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
- Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
ABSTRACT Background The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI). We assessed the feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants. Methods In this phase 2B, ...
New malaria vaccine more than 50 percent effective
New malaria vaccine more than 50 percent effective
blog.foreignpolicy.com — Results of the latest malaria vaccine trials will be published today in The New England Journal of... Medicine , and from the looks of it, the news is good--fantastic, in fact. "We are closer than every before to having a malaria vaccine for use ... (more) New malaria vaccine more than 50 percent effective
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
content.nejm.org — Figure 1. Screening, Randomization, and Follow-up of Study Participants. The 177 children who were deemed ineligible at... screening had an age outside the acceptable range (67 children), an acute disease at enrollment (23), a serious illness on clinical ... (more) - Efficacy of RTS,S/AS01E Vaccine against Malaria in ...
Malaria Vaccine Effective in Latest Trials - US News and World Report
Malaria Vaccine Effective in Latest Trials - US News and World Report
health.usnews.com — HealthDay Reporter MONDAY, Dec. 8 (HealthDay News) Results from two phase II trials in Africa show that... a new malaria vaccine is effective at preventing both infection and the mosquito-borne disease itself in infants and children."Malaria is killing ... (more) Malaria Vaccine Effective in Latest Trials - US News and ...
Comments
Blog Reactions

Malaria Vaccine Effective in Latest Trials
Democratic Underground Latest Breaking News — ... burden of malaria disease," he added. The findings were published online Dec. 8 in the New England Journal of Medicine. Read more: http://health.usnews.com/articles/health/healthday/2008... One of medicine's Holy Grail's. The NEJM articles are currently free online: Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age http://content.nejm.org/cgi/content/full/NEJMoa0807381 Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants http://content.nejm.org/cgi/content/full/NEJMoa0807773

Great News
Political Animal — Great News Wonderful news from the New England Journal of Medicine ( 1 , 2 ), summarized by FP Passport : Results of the latest malaria vaccine trials will be published today in The New England Journal of Medicine, and from the looks of it, the news is good--fantastic, in fact. "We are closer than every before to having a malaria vaccine for use by children in Africa, says Christian Lucq, director of the PATH Malaria Vaccine Initiative. First, some background: The new trials use a vaccine candidate known as RTSS, the most clinically advanced malaria vaccine in ...

Great News
Obsidian Wings — ... by hilzoy Wonderful news from the New England Journal of Medicine (1, 2), summarized by FP Passport: Results of the latest malaria vaccine trials will be published today in The New England Journal of Medicine, and from the looks of it, the news is good--fantastic, in fact. "We are closer than every before to having a malaria vaccine for use by children in Africa, says Christian Lucq, director of the PATH Malaria Vaccine Initiative. First, some background: The new trials use a vaccine ...

Related Content
The Impact of Malaria, a Leading Cause of Death Worldwide | CDC Malaria
cdc.gov 12/9/2008 — Pregnant woman having a fingerprick performed by a health worker for diagnosis of malaria in a semi-open clinic
'Airport malaria' -- cause for concern in the US
eurekalert.org 11/18/2008 — 'Airport malaria' -- cause for concern in the US
DEFEAT MALARIA? Yes we can. Last week, two studies published in the New England Journal of Medic…
pajamasmedia.com 12/18/2008 — DEFEAT MALARIA? Yes we can. Last week, two studies published in the New England Journal of Medicine reported promising news about a malaria vaccine candidate that our company, GlaxoSmithKline, is developing in collaboration with the Malaria ...